CN112370470B - Microecological preparation for reconstructing intestinal microecology - Google Patents

Microecological preparation for reconstructing intestinal microecology Download PDF

Info

Publication number
CN112370470B
CN112370470B CN202011294300.7A CN202011294300A CN112370470B CN 112370470 B CN112370470 B CN 112370470B CN 202011294300 A CN202011294300 A CN 202011294300A CN 112370470 B CN112370470 B CN 112370470B
Authority
CN
China
Prior art keywords
intestinal
preparation
solution
microecological preparation
microecological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011294300.7A
Other languages
Chinese (zh)
Other versions
CN112370470A (en
Inventor
周平红
蔡明琰
石国良
王羽娟
林卫军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomson Biotech Xiamen Pte Ltd
Zhongshan Hospital Fudan University
Original Assignee
Thomson Biotech Xiamen Pte Ltd
Zhongshan Hospital Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomson Biotech Xiamen Pte Ltd, Zhongshan Hospital Fudan University filed Critical Thomson Biotech Xiamen Pte Ltd
Priority to CN202011294300.7A priority Critical patent/CN112370470B/en
Publication of CN112370470A publication Critical patent/CN112370470A/en
Application granted granted Critical
Publication of CN112370470B publication Critical patent/CN112370470B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium

Abstract

The invention relates to a microecological preparation for reconstructing intestinal microecology. Specifically, the invention provides a microecological preparation, which comprises strains, sodium alginate, konjak mannan, xylan, L-arabinose and chitosan; the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof. The microecological preparation can remarkably improve the recovery and reconstruction of intestinal microecology after intestinal tract preparation for intestinal tract operation, improve intestinal tract microecological imbalance of the intestinal tract operation, and improve side effects such as the rise of diamine oxidase level, the rise of intestinal mucosa permeability, the damage of intestinal mucosa barrier and the like.

Description

Microecological preparation for reconstructing intestinal microecology
Technical Field
The invention relates to the field of biological agents, in particular to a microecological agent for reconstructing intestinal microecology.
Background
The intestinal microecological system refers to an ecological system formed by densely colonising different flora on the intestinal mucosa surface of a human body and jointly colonising the intestinal mucosa surface and the colonising environment. It is the most important and most studied system among five major micro-ecosystems of the human body, such as gastrointestinal tract, oral cavity, genitourinary tract, skin, and respiratory tract. The intestinal micro-ecological system is widely involved in multiple physiological and pathological activities such as metabolism, mucosal barrier, immune regulation and the like of a human body, and is an important barrier for maintaining the health of the human body. These colonised intestinal flora are the "resident" of the intestine and play a vital role in regulating the intestinal health of the human body. .
The microecological preparation is a combined preparation prepared from normal microbiota beneficial to a host, metabolites thereof or growth promoting substances thereof, and the like, and can achieve the purpose of regulating and maintaining the microecological balance of the host through the actions of biological barriers, adhesion field planting, and the like, thereby improving the health state of the host.
In the enteroscopy, in order to obtain a clear visual field and ensure high quality of the examination, a strategy for preparing intestinal tracts before operation is not necessary, the intestinal tracts are cleaned before enteroscopy or abdominal operation is performed, if feces remain, the effect of the examination cannot be achieved when enteroscopy is performed, and gastrointestinal tract contents pollute abdominal cavities and influence the visual field of the operation when abdominal operation is performed. In terms of medicament selection, the current clinical strong recommended drugs for intestinal tract preparation are magnesium sulfate and polyethylene glycol. During the process of intestinal tract cleaning, the intestinal mucosa is inevitably damaged, the intestinal microecological system is disturbed, and even in some inflammatory bowel disease cases, the intestinal tract preparation may induce relevant clinical symptoms. Reports indicate that the abundance of intestinal flora decreases rapidly after intestinal preparation in healthy people, taking longer to restore normal levels. Researchers have compared and studied intestinal flora before and after intestinal preparation of colorectal cancer patients, and found that the levels of probiotics such as bifidobacteria, lactobacillus and the like are obviously reduced after the operation of the patients. These studies demonstrate that the scouring action on the intestinal flora during intestinal preparation can directly lead to a reduction and a change of the intestinal flora, but at the same time provide an opportunity to re-establish intestinal micro-ecology in humans.
In the traditional strategy for restoring the intestinal microecological system, the used microecological preparation has the advantages that the survival rate of probiotics in the microecological preparation can not be ensured when the probiotics pass through the gastrointestinal tract, and the recovery and improvement of the probiotics such as bifidobacteria, lactobacillus and the like on intestinal microecologics after intestinal tract operation after intestinal tract preparation are greatly limited. Meanwhile, most of the prebiotics contained in the composition are soluble fructo-oligosaccharides, galacto-oligosaccharides, inulin and the like, so that the composition is single in nutrition, the diversity of the nutrition foundation of intestinal flora cannot be guaranteed, and the repairing effect is not ideal.
Therefore, there is a need in the art to develop a formulation that combines intestinal cleansing with recovery/reconstitution/construction of human intestinal micro-ecology.
Disclosure of Invention
The invention aims to provide a microecological preparation which can be used for reconstructing intestinal microecology, and can also be used for reducing the level of diamine oxidase, inhibiting the increase of intestinal mucosa permeability, protecting intestinal mucosa barrier, promoting intestinal tract exhaust, improving intestinal tract obstruction or intestinal peduncle and/or improving side effects after intestinal tract operation.
The first aspect of the invention provides a microecological preparation, which comprises a strain, sodium alginate, konjak mannan, xylan, L-arabinose and chitosan;
the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (1.5-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (4-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-3): (0.2-0.4): (5-7): (0.8-1.2).
Preferably, the xylan is arabinoxylan.
Preferably, the microecological preparation further comprises levan.
Preferably, in the microecological preparation, the sodium alginate, the konjak mannan, the xylan and the L-arabinose are used for carrying out the first embedding, and then the chitosan is used for carrying out the second embedding.
Preferably, the ratio (CFU: g) of the lactobacillus to the sodium alginate is 10 9 ～10 10 :0.1 to 0.5, preferably 10 9 ～10 10 ：0.1-0.3。
Preferably, the ratio (CFU: g) of the bifidobacterium to the sodium alginate is 10 9 ～10 10 :0.1 to 0.5, preferably 10 9 ～10 10 ：0.1-0.3。
Preferably, the microecological formulation is prepared by a process comprising the steps of:
(1) Mixing sodium alginate, konjak mannan, xylan and L-arabinose with water to obtain a polysaccharide solution;
(2) Mixing the polysaccharide solution obtained in the step (1) with a bacterial suspension to obtain a bacterial-containing mixed solution, wherein the bacterial suspension contains one or more bacterial species selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof;
(3) Adding the mixed solution containing bacteria obtained in the step (2) into a calcium chloride solution, standing and filtering to obtain a precipitated primary microecological preparation;
(4) And (3) adding the primary microecological preparation obtained in the step (3) into chitosan solution, and embedding to obtain the microecological preparation.
Preferably, the polysaccharide solution further comprises levan.
Preferably, the sodium alginate is present in the polysaccharide solution in an amount of 0.5 to 10wt%, preferably 1 to 5wt%, more preferably 1 to 3wt%, based on the total weight of the polysaccharide solution.
Preferably, the konjac mannan is present in the polysaccharide solution in an amount of 0.1 to 0.6wt%, preferably 0.1 to 0.5wt%, more preferably 0.2 to 0.4wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 1 to 10wt%, preferably 1.5 to 8wt%, more preferably 5 to 7wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 2 to 10wt%, preferably 4 to 8wt%, more preferably 5 to 7wt%, based on the total weight of the polysaccharide solution.
Preferably, the content of L-arabinose in the polysaccharide solution is 0.2-2wt%, preferably 0.5-1.5wt%, more preferably 0.8-1.2wt%, based on the total weight of the polysaccharide solution.
Preferably, the bacterial suspension contains water.
Preferably, the medium of the bacterial suspension comprises water.
Preferably, the concentration of the lactobacillus in the bacterial suspension is 10 9 ～10 10 CFU/ml。
Preferably, the concentration of the bifidobacterium in the bacterial suspension is 10 9 ～10 10 CFU/ml。
Preferably, in step (2), the volume ratio of polysaccharide solution to bacterial suspension is 2-30:1, preferably 5-20:1, more preferably 5-15:1, optimally 8-12:1.
preferably, in step (3), the concentration of the calcium chloride solution is 0.1 to 0.5mol/L, preferably 0.2 to 0.4mol/L.
Preferably, in the step (3), the rest time is 25-35min.
Preferably, in step (3), the resting temperature is 20-30 ℃.
Preferably, in step (3), the precipitate is washed with water in said filtration step.
Preferably, in step (4), the chitosan solution is prepared by the following method:
and (3) dissolving chitosan in an acetic acid solution, and regulating the pH to 5.5-6.5 to obtain a chitosan solution.
Preferably, the concentration of the acetic acid solution is 0.08-0.12mol/L.
Preferably, the chitosan solution has a chitosan content of 0.05-1.2wt%, preferably 0.1-1.0wt%, more preferably 0.2-0.6wt%, based on the total weight of the chitosan solution.
Preferably, the pH is adjusted with a base.
Preferably, the base is selected from the group consisting of: sodium hydroxide, potassium hydroxide, or a combination thereof.
Preferably, in step (4), the chitosan solution is prepared by the following method:
2.0-6.0g of chitosan is dissolved by 900-980mL of 0.08-0.12mol/L acetic acid solution, the pH value of the solution is regulated to 6.0 by NaOH solution with the concentration of 0.8-1.2mol/L after the chitosan is completely dissolved, and the chitosan solution is obtained after filtration and volume fixing to 1000 mL.
Preferably, in the step (4), the weight-to-volume ratio (g/ml) of the primary microecological preparation to the chitosan solution is 10-20:80-120.
Preferably, in the step (4), the weight ratio of the primary microecological preparation to the chitosan is 10-20:2-6.
Preferably, in step (4), the embedding comprises a stirring step.
Preferably, the stirring speed is 160-200r/min.
Preferably, the temperature of the stirring is 20-37 ℃.
Preferably, the stirring time is 20-40min.
Preferably, in step (4), the embedding includes the steps of:
adding the primary microecological preparation obtained in the step (3) into chitosan solution, stirring at a constant temperature of 160-200r/min for 20-40min at 20-37 ℃, filtering, collecting precipitate, and washing with NaCl solution to obtain the microecological preparation.
Preferably, the concentration of the NaCl solution is 8-9.0g/L NaCl.
Preferably, the microecological preparation is a pharmaceutical preparation, a food preparation or a health-care product preparation.
Preferably, the microecological preparation also comprises other pharmaceutically, food or health-care acceptable carriers.
Preferably, the health product comprises a dietary supplement.
Preferably, the formulation of the microecological preparation is an oral preparation.
Preferably, the microecological preparation is a tablet, a capsule, an oral liquid, a granule, a powder or a syrup.
In a second aspect the present invention provides the use of a probiotic according to the first aspect of the present invention for the preparation of a composition or formulation for one or more uses selected from the group consisting of: (i) for improving intestinal microecology; (ii) reducing diamine oxidase levels; (iii) inhibiting an increase in intestinal mucosa permeability; (iv) protecting the intestinal mucosal barrier; and/or (vii) ameliorate post-intestinal surgery side effects.
Preferably, the improvement comprises reconstruction and/or restoration.
Preferably, the intestinal microecology comprises a microbial ecology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal tract cleaning and/or intestinal tract medical operation.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal preparation.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal surgery.
Preferably, the intestinal surgery comprises intestinal resection.
Preferably, the intestinal surgery comprises ileocecum intestinal resection.
Preferably, the intestinal surgery comprises intestinal cancer surgery.
Preferably, the cancer comprises rectal cancer, colon cancer or colorectal cancer.
Preferably, the intestinal surgery includes intestinal surgery performed after intestinal preparation.
Preferably, the intestinal microecology comprises intestinal microecology after an intestinal operation, and the intestinal operation comprises intestinal operation performed after intestinal preparation.
Preferably, the intestinal preparation comprises intestinal preparation of an intestinal clearing agent selected from the group consisting of: magnesium sulfate, mannitol, sorbitol, L-arabinose, polyethylene glycol, or a combination thereof.
Preferably, the intestinal surgery comprises rectal cancer surgery, colon cancer surgery or straight/colon cancer surgery.
Preferably, the diamine oxidase level comprises plasma, serum or whole blood levels of diamine oxidase.
Preferably, said inhibiting the increase in intestinal mucosa permeability comprises inhibiting the increase in intestinal mucosa permeability by decreasing diamine oxidase levels.
Preferably, the diamine oxidase level comprises a post-intestinal surgery diamine oxidase level.
Preferably, protecting the intestinal mucosal barrier comprises protecting the intestinal mucosal barrier by inhibiting an increase in intestinal mucosal permeability.
Preferably, the increase in intestinal mucosa permeability comprises an increase in intestinal mucosa permeability after an intestinal operation.
Preferably, the intestinal mucosal barrier comprises an intestinal mucosal barrier after an intestinal operation.
Preferably, the post-intestinal surgery side effects are selected from the group consisting of: intestinal dysbiosis, elevated diamine oxidase levels, elevated intestinal mucosal permeability, disruption of intestinal mucosal barrier, or combinations thereof.
Preferably, the intestinal microecology comprises a microbial ecology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal dysbiosis comprises a dysregulation of a microorganism selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the disorder comprises a decrease (e.g., a decrease in the amount).
Preferably, the composition or preparation is a pharmaceutical composition or preparation, a food composition or preparation, or a health care composition or preparation.
Preferably, the composition or formulation further comprises other pharmaceutically, food-or nutraceutical acceptable carriers.
Preferably, the health product comprises a dietary supplement.
Preferably, the composition or the preparation is in the form of an oral preparation.
Preferably, the composition is in the form of tablet, capsule, oral liquid, granule, powder or syrup.
It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions.
Detailed Description
The invention develops a microecological preparation which can remarkably improve the survival rate of probiotics such as lactobacillus and bifidobacterium in gastrointestinal fluid, and can remarkably improve the recovery and reconstruction of intestinal microecology after intestinal tract operation after intestinal tract preparation, improve intestinal microecological imbalance of intestinal tract operation, and improve the side effects of diamine oxidase level rise, intestinal mucosa permeability rise, intestinal mucosa barrier damage and the like. Therefore, the microecological preparation provided by the invention has an excellent improving effect on intestinal operation patients after intestinal preparation.
Terminology
As used herein, the terms "comprising," including, "and" containing "are used interchangeably to include not only the open definition, but also the semi-closed, and closed definition, including" consisting of … …, "" consisting essentially of … ….
Exemplary embodiments of the present application are described below, including various details of embodiments of the present application to facilitate understanding, which should be considered as merely exemplary. Accordingly, one of ordinary skill in the art will recognize that various changes and modifications of the embodiments described herein can be made without departing from the scope and spirit of the present application. Also, descriptions of well-known functions and constructions are omitted in the following description for clarity and conciseness.
Microecological preparation
The microecological preparation provided by the invention can recover/rebuild/construct human intestinal microecology after the intestinal tract is cleaned. After intestinal tract operation, the intestinal tract preparation is carried out by taking a microecological preparation containing probiotics such as high-survival-rate microorganisms such as lactobacillus and bifidobacterium to improve (reconstruct or restore) intestinal tract microecology, and the microecological preparation can also provide nutrients for the whole intestinal tract probiotics, ensure the diversity of nutrients required by the internal colonisation and growth of the whole intestinal tract probiotics in the intestinal tract, promote the growth of the probiotics in the intestinal tract, restore the effects of participating in metabolic regulation, intestinal tract barrier protection and the like, so that the microbial beneficial to the human health is preferentially cultivated, the propagation of intestinal tract harmful bacteria is inhibited, the aim and the effect of recovering/reconstructing/constructing the human microecological are achieved, and finally the aim of improving/treating constipation, diarrhea, abdominal distension and other clinical symptoms related to the intestinal tract is realized.
After the intestinal tract is cleaned by medicines such as magnesium sulfate, polyethylene glycol or a composition thereof, and the like, the probiotics and harmful bacteria originally attached to the surface of the intestinal mucosa are discharged along with excrement along with the cleaning medicines and the cleaning liquid, and the original intestinal probiotics serve as the 'occupying' protection effect of the intestinal mucosa and disappear along with the cleaning medicines and the cleaning liquid, so that the physical barrier effect of the intestinal probiotics is urgently required to be reestablished. The microbial ecological agent disclosed by the invention is eaten by patients (intestinal healthy people, constipation people and other people with gastrointestinal diseases) in a neutral period of gastrointestinal tract emptying (comprising the condition that the original beneficial or harmful bacteria in the intestinal tract are all removed), so that a large number of microorganisms beneficial to human health can be preferentially cultured, meanwhile, the intestinal probiotics are recovered to participate in metabolic regulation such as secretion of intestinal mucus, the recovery of damaged intestinal mucosa is accelerated, the permeability of the intestinal mucosa is reduced to the health level of an individual, and the effect of reconstructing the human intestinal microecology is achieved.
The invention provides a microecological preparation, which comprises strains, sodium alginate, konjak mannan, xylan, L-arabinose and chitosan;
the strain is selected from the following group: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
As used herein, sodium alginate is a byproduct of brown algae kelp or gulfweed after extracting iodine and mannitol, and its molecule is formed by bonding β -D-mannuronic acid (β -D-mannuronic, M) and α -L-guluronic acid (α -L-guluronic, G) in (1→4), and is a natural polysaccharide, CAS accession no: 9005-38-3.
As used herein, konjak mannan is a major component contained in konjak, CAS accession no: 37220-17-0. The konjak mannan is white powder, can be swelled by adding water, and is soluble in water but insoluble in organic solvents such as acetone, chloroform and the like. The konjak mannan is also called konjak flour, and the main components of the konjak mannan are mannan and glucose, and the konjak mannan is white or cream to light brown powder. Can be used as a gelling agent, a thickener, an emulsifier, a stabilizer, and a film forming agent.
As used herein, the backbone of xylan is formed from xylose linked via β -1, 4-glycosidic linkages. Typically, the xylan is arabinoxylan. Arabinoxylan is a hemicellulose polysaccharide, is a main existence form of cereal or herbal cell wall xylan, and a macromolecular main chain of the arabinoxylan is formed by connecting xylose through beta-1, 4-glycosidic bonds, and a branched chain structure contains an arabinose substituent.
As used herein, L-arabinose, also known as arabinose, pectin sugar; is an aldopentose, CAS accession number: 5328-37-0.
As used herein, chitosan (chitosan) has many unique properties of biodegradability, cell affinity, and biological effect, among natural polysaccharides, basic polysaccharides, CAS accession no: 9012-76-4.
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (1.5-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-5): (0.1-0.5): (4-8): (0.5-1.5).
Preferably, the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-3): (0.2-0.4): (5-7): (0.8-1.2).
Preferably, the microecological preparation further comprises levan.
Preferably, in the microecological preparation, the sodium alginate, the konjak mannan, the xylan and the L-arabinose are used for carrying out the first embedding, and then the chitosan is used for carrying out the second embedding.
Preferably, the ratio (CFU: g) of the lactobacillus to the sodium alginate is 10 9 ～10 10 :0.1 to 0.5, preferably 10 9 ～10 10 ：0.1-0.3。
Preferably, the ratio (CFU: g) of the bifidobacterium to the sodium alginate is 10 9 ～10 10 :0.1 to 0.5, preferably 10 9 ～10 10 ：0.1-0.3。
In a preferred embodiment of the present invention, the microecological formulation is prepared by a process comprising the steps of:
(1) Mixing sodium alginate, konjak mannan, xylan and L-arabinose with water to obtain a polysaccharide solution;
(2) Mixing the polysaccharide solution obtained in the step (1) with a bacterial suspension to obtain a bacterial-containing mixed solution, wherein the bacterial suspension contains one or more bacterial species selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof;
(3) Adding the mixed solution containing bacteria obtained in the step (2) into a calcium chloride solution, standing and filtering to obtain a precipitated primary microecological preparation;
(4) And (3) adding the primary microecological preparation obtained in the step (3) into chitosan solution, and embedding to obtain the microecological preparation.
In a preferred embodiment of the present invention, the xylan is arabinoxylan.
Preferably, the polysaccharide solution further comprises levan.
Preferably, the sodium alginate is present in the polysaccharide solution in an amount of 0.5 to 10wt%, preferably 1 to 5wt%, more preferably 1 to 3wt%, based on the total weight of the polysaccharide solution.
Preferably, the konjac mannan is present in the polysaccharide solution in an amount of 0.1 to 0.6wt%, preferably 0.1 to 0.5wt%, more preferably 0.2 to 0.4wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 2 to 10wt%, preferably 4 to 8wt%, more preferably 5 to 7wt%, based on the total weight of the polysaccharide solution.
Preferably, the xylan is present in the polysaccharide solution in an amount of 1 to 10wt%, preferably 1.5 to 8wt%, more preferably 5 to 7wt%, based on the total weight of the polysaccharide solution.
The content of L-arabinose in the polysaccharide solution is 0.2-2wt%, preferably 0.5-1.5wt%, more preferably 0.8-1.2wt%, based on the total weight of the polysaccharide solution.
Preferably, the bacterial suspension contains water.
Preferably, the medium of the bacterial suspension comprises water.
Preferably, the concentration of the lactobacillus in the bacterial suspension is 10 9 ～10 10 CFU/ml。
Preferably, the concentration of the bifidobacterium in the bacterial suspension is 10 9 ～10 10 CFU/ml。
Preferably, in step (2), the volume ratio of polysaccharide solution to bacterial suspension is 2-30:1, preferably 5-20:1, more preferably 5-15:1, optimally 8-12:1.
preferably, in step (3), the concentration of the calcium chloride solution is 0.1 to 0.5mol/L, preferably 0.2 to 0.4mol/L.
Preferably, in the step (3), the rest time is 25-35min.
Preferably, in step (3), the resting temperature is 20-30 ℃.
Preferably, in step (3), the precipitate is washed with water in said filtration step.
Preferably, in step (4), the chitosan solution is prepared by the following method:
and (3) dissolving chitosan in an acetic acid solution, and regulating the pH to 5.5-6.5 to obtain a chitosan solution.
Preferably, the concentration of the acetic acid solution is 0.08-0.12mol/L.
Preferably, the chitosan solution has a chitosan content of 0.05-1.2wt%, preferably 0.1-1.0wt%, more preferably 0.2-0.6wt%, based on the total weight of the chitosan solution.
Preferably, the pH is adjusted with a base.
Preferably, the base is selected from the group consisting of: sodium hydroxide, potassium hydroxide, or a combination thereof.
Preferably, in step (4), the chitosan solution is prepared by the following method:
2.0-6.0g of chitosan is dissolved by 900-980mL of 0.08-0.12mol/L acetic acid solution, the pH value of the solution is regulated to 6.0 by NaOH solution with the concentration of 0.8-1.2mol/L after the chitosan is completely dissolved, and the chitosan solution is obtained after filtration and volume fixing to 1000 mL.
Preferably, in the step (4), the weight-to-volume ratio (g/ml) of the primary microecological preparation to the chitosan solution is 10-20:80-120.
Preferably, in the step (4), the weight ratio of the primary microecological preparation to the chitosan is 10-20:2-6.
Preferably, in step (4), the embedding comprises a stirring step.
Preferably, the stirring speed is 160-200r/min.
Preferably, the temperature of the stirring is 20-37 ℃.
Preferably, the stirring time is 20-40min.
Preferably, in step (4), the embedding includes the steps of:
adding the primary microecological preparation obtained in the step (3) into chitosan solution, stirring at a constant temperature of 160-200r/min for 20-40min at 20-37 ℃, filtering, collecting precipitate, and washing with NaCl solution to obtain the microecological preparation.
Preferably, the concentration of the NaCl solution is 8-9.0g/L NaCl.
Preferably, the microecological preparation is a pharmaceutical preparation, a food preparation or a health-care product preparation.
Preferably, the microecological preparation also comprises other pharmaceutically, food or health-care acceptable carriers.
Preferably, the health product comprises a dietary supplement.
Preferably, the formulation of the microecological preparation is an oral preparation.
Preferably, the microecological preparation is a tablet, a capsule, an oral liquid, a granule, a powder or a syrup.
Use of the same
Typically, the present invention provides a use of a probiotic according to the invention for improving intestinal microecology.
In a preferred embodiment of the present invention, the intestinal microecology comprises a microbial ecology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal tract cleaning and/or intestinal tract medical operation.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal preparation.
Preferably, the intestinal microecology comprises intestinal microecology after intestinal surgery.
Preferably, the bowel surgery includes bowel cancer surgery, such as open radical colorectal cancer resection surgery.
Preferably, the cancer comprises rectal cancer, colon cancer or colorectal cancer.
Preferably, the intestinal surgery comprises intestinal resection.
Preferably, the intestinal surgery comprises ileocecum intestinal resection.
Typically, the bowel surgery includes bowel surgery performed after bowel preparation.
Typically, the intestinal microecology comprises intestinal microecology after an intestinal operation, and the intestinal operation comprises an intestinal operation performed after intestinal preparation.
Preferably, the intestinal preparation comprises intestinal preparation of an intestinal clearing agent selected from the group consisting of: magnesium sulfate, mannitol, sorbitol, L-arabinose, polyethylene glycol, or a combination thereof.
Preferably, the intestinal surgery comprises rectal cancer surgery, colon cancer surgery or straight/colon cancer surgery.
In another preferred embodiment of the invention, the invention provides a probiotic formulation according to the invention for use in reducing diamine oxidase levels; inhibiting increase in intestinal mucosa permeability; protecting the intestinal mucosal barrier; and/or to improve the side effects after intestinal surgery.
Preferably, the diamine oxidase level comprises plasma, serum or whole blood levels of diamine oxidase.
Preferably, said inhibiting the increase in intestinal mucosa permeability comprises inhibiting the increase in intestinal mucosa permeability by decreasing diamine oxidase levels.
Preferably, the diamine oxidase level comprises a post-intestinal surgery diamine oxidase level.
Preferably, protecting the intestinal mucosal barrier comprises protecting the intestinal mucosal barrier by inhibiting an increase in intestinal mucosal permeability.
Preferably, the increase in intestinal mucosa permeability comprises an increase in intestinal mucosa permeability after an intestinal operation.
Preferably, the intestinal mucosal barrier comprises an intestinal mucosal barrier after an intestinal operation.
Preferably, the post-intestinal surgery side effects are selected from the group consisting of: intestinal dysbiosis, elevated diamine oxidase levels, elevated intestinal mucosal permeability, disruption of intestinal mucosal barrier, or combinations thereof.
Preferably, the intestinal microecology comprises a microbial ecology selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the intestinal dysbiosis comprises a dysregulation of a microorganism selected from the group consisting of: lactobacillus, bifidobacterium, lactobacillus reuteri, lactobacillus acidophilus, lactobacillus casei, bacteroides, clostridium, bacillus subtilis, lactobacillus rhamnosus, or a combination thereof.
Preferably, the disorder comprises a decrease (e.g., a decrease in the amount).
Composition and method for producing the same
The invention also provides a composition which can be a pharmaceutical composition, a food composition or a health care product composition.
The composition also comprises a carrier acceptable in pharmacy, food or health care products.
As used herein, the term "pharmaceutically, food-or nutraceutical acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers suitable for human or animal use, and of sufficient purity and low enough toxicity.
It will be appreciated that in the present invention, the carrier is not particularly limited, and materials commonly used in the art, or prepared by a conventional method, or purchased from the market may be selected. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. methylcellulose, ethylcellulose, hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g. soybean oil, sesame oil, etc.), polyols (e.g. propylene glycol, glycerol, sorbitol, etc.), emulsifiers (e.g. tween), humectants (e.g. sodium lauryl sulfate), buffers, chelating agents, thickeners, pH adjusting agents, transdermal enhancers, colorants, flavouring agents, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.
In the present invention, the dosage forms of the pharmaceutical composition include, but are not limited to, oral formulations.
Representative dosage forms include (but are not limited to): tablets, capsules, oral liquids, granules, powders or syrups.
The main technical effects obtained by the invention include:
1. the invention develops a microecological preparation, and the used microecological preparation can obviously improve the survival rate of probiotics such as lactobacillus, bifidobacterium and the like in gastrointestinal fluid.
2. The microecological preparation can remarkably improve the recovery and reconstruction of intestinal microecology after intestinal tract preparation for intestinal tract operation, improve intestinal tract microecological imbalance of the intestinal tract operation, and improve side effects such as the rise of diamine oxidase level, the rise of intestinal mucosa permeability, the damage of intestinal mucosa barrier and the like. Therefore, the microecological preparation provided by the invention has an excellent improving effect on intestinal operation patients after intestinal preparation.
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention.
Example 1 preparation of a microecological formulation
The embodiment provides a preparation method of a microecological preparation, which comprises the following steps:
1. strain activation and preparation of concentrated bacterial suspensions
All glassware and solutions were sterilized at 121℃for 20min. Inoculating the frozen strain (bifidobacterium) into MRS liquid culture medium, and performing passage for several times at 37 ℃ until the strain is completely activated. Centrifuging culture solution at end of log phase at 4deg.C for 8-12 min, removing supernatant, washing bacterial mud with sterile physiological saline twice, and re-suspending bacterial mud in sterile water to obtain concentrated bacterial suspension, wherein in the bacterial suspension, the bacterial concentration of Bacillus bifidus is 10 9 ～10 10 CFU/ml。
2. Preparation of primary microecological preparation
And mixing sodium alginate, konjak mannan, arabinoxylan and L-arabinose with water to obtain a polysaccharide mixed solution, wherein the content of the sodium alginate, the konjak mannan, the arabinoxylan and the L-arabinose is 2wt%, 0.3wt%, 6wt% and 1wt%, respectively, based on the total weight of the polysaccharide mixed solution. Sterilizing the polysaccharide mixed solution at 121deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with the polysaccharide mixed solution according to the volume ratio of 1:10, extruding the mixture into 0.3mol/L calcium chloride solution by using a syringe, standing the mixture at the room temperature of 25 ℃ for 30min, filtering the mixture, and washing the mixture with sterile water for 2 times to obtain the precipitate primary microecological preparation.
3. Preparation of microecological preparation
4.0g of chitosan was dissolved in 950mL of 0.1mol/L acetic acid solution, and after complete dissolution, the pH of the solution was adjusted to 6.0 with 1.0mol/L NaOH solution, and the solution was filtered and then fixed to 1000mL to obtain a chitosan solution. 15.0g of the primary microecological preparation prepared in the step 2 is added into 100mL of prepared chitosan solution, the mixture is stirred for 30min at the constant temperature of 180r/min at 37 ℃, the gauze is used for filtering and collecting the secondarily embedded microecological preparation, and the secondarily embedded microecological preparation is obtained by low-temperature freeze drying after being washed twice with sterile 8.5g/L NaCl solution.
Example 2 preparation of a microecological formulation
The embodiment provides a method for preparing a microecological preparation, which comprises the following steps:
1. strain activation and preparation of concentrated bacterial suspensions
Step 1 was prepared as in example 1.
2. Preparation of primary microecological preparation
Mixing sodium alginate with water to obtain sodium alginate solution, wherein the content of sodium alginate is 2wt%, based on the total weight of the sodium alginate solution, sterilizing the sodium alginate solution at 121deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with sodium alginate solution according to the volume ratio of 1:10, extruding the mixture into 0.3mol/L calcium chloride solution by using a syringe, standing the mixture at the room temperature of 25 ℃ for 30min, filtering the mixture, and washing the mixture with sterile water for 2 times to obtain the precipitate primary microecological preparation.
3. Preparation of microecological preparation
Step 3 of the same preparation as in example 1 is performed to prepare a microecological preparation.
EXAMPLE 3 preparation of microecological formulation
The embodiment provides a method for preparing a microecological preparation, which comprises the following steps:
1. strain activation and preparation of concentrated bacterial suspensions
Step 1 was prepared as in example 1.
2. Preparation of primary microecological preparation
And mixing konjak mannan, arabinoxylan and L-arabinose with water to obtain a polysaccharide mixed solution, wherein the contents of konjak mannan, arabinoxylan and L-arabinose are respectively 0.3wt%, 6wt% and 1wt%, based on the total weight of the polysaccharide mixed solution. Sterilizing the polysaccharide mixed solution at 121deg.C for 20min, and cooling to room temperature. And (2) uniformly mixing the bacterial suspension obtained in the step (1) with a polysaccharide solution according to a volume ratio of 1:10, extruding the mixture into a 0.3mol/L calcium chloride solution by using a syringe, standing the mixture at room temperature of 25 ℃ for 30min, filtering the mixture, and washing the mixture with sterile water for 2 times to obtain a precipitate primary microecological preparation.
43. Preparation of microecological preparation
Step 3 of the same preparation as in example 1 is performed to prepare a microecological preparation.
Experimental example 1 of Effect
The experimental example of the effect examines the influence of different embedding methods on the survival rate of bifidobacteria
Test preparation: artificial gastric juice/high salt bile liquid preparation
(1) Preparing artificial gastric juice: preparing artificial gastric juice containing 3% pepsin, 2% NaCl and pH2.0, sterilizing the prepared artificial gastric juice with 0.22 μm membrane, and placing in refrigerator for use.
(2) Preparing artificial intestinal juice: preparing artificial intestinal juice containing 1% pancreatin and having pH of 6.8, sterilizing the prepared artificial intestinal juice with 0.22 μm membrane, and placing in a refrigerator at 4deg.C for use.
(3) Preparing a high-content salt solution: uniformly dispersing bile salt in phosphate buffer solution to make its final concentration be 2g/L, then using 0.1mol/L NaOH solution to regulate pH value of said mixed liquor to 6.8, filtering and sterilizing, placing it in refrigerator for use.
The test process comprises the following steps:
9mL of the prepared artificial gastric juice, artificial intestinal juice and high-bile salt solution are respectively taken, 1g of the microecological preparation or the primary microecological preparation prepared in examples 1-3 is respectively added, shaking is carried out for 120min at 180r/min at 37 ℃ in a shaking table, the mixture is taken out, viable bacteria are counted, meanwhile, the viable bacteria are compared with bacterial suspension (1 m L), and the results are shown in Table 1:
table 1 effect of different formulations on bifidobacterium survival (n=3, mean value)
Figure BDA0002784896070000151
Figure BDA0002784896070000161
From Table 1, it is understood that the probiotics prepared in examples 1-3 are capable of improving the survival rate of bifidobacteria in gastrointestinal fluids, thereby prolonging the survival time of bifidobacteria in gastrointestinal fluids.
Experimental example 2 of Effect
The experimental example of the effect examines the improvement effect of the microecological preparation on the microbial flora after the preparation of the intestinal tract
1. The test method comprises the following steps:
healthy SD rats were selected, self-adapted for one week after purchase, and then randomly divided into 5 groups of 8 animals each, i.e., male and female halves, respectively, experimental group 1, experimental group 2, experimental group 3, experimental group 4 and control group, and rats of experimental group 1, experimental group 2, experimental group 3 and experimental group 4 were given 33wt% magnesium sulfate solution (magnesium sulfate administration dose of 10 ml/kg) by intragastric administration on day 1 for intestinal preparation, fasted without water inhibition, and rats of experimental groups 1-4 were operated on the 2 nd morning respectively, and the operation procedure was as follows: after anesthesia with 5ml/kg of 2% sodium pentobarbital, a 1cm section of intestine was excised 5cm proximal to the ileocecum and 50ml/kg of 5% saline was subcutaneously injected.
Rats of experimental group 1, experimental group 2, and experimental group 3 were respectively delivered with physiological saline by intragastric administration of the probiotics prepared in examples 1-3 1-5 days after surgery (bifidobacterium administration dose per rat of experimental group 1-3 was 3.5×10 7 CFU bacteria count/220 g.body weight), rats of experimental group 4 were perfused with normal saline, free diet. SD rats of the control group were fed with normal diet without any preparation and surgical treatment of magnesium sulfate intestinal tract, as a blank control.
On the 6 th day after surgery, each group of rats was sacrificed after tail-breaking blood collection, and 1g of blind feces was retrieved for bacterial culture.
The mode of administration for each experimental group was as follows:
experiment group 1: intestinal tract preparation and post-operative administration of the probiotic prepared in example 1;
experiment group 2: intestinal tract preparation and post-operative administration of the probiotic prepared in example 2;
experiment group 3: intestinal tract preparation and post-operative administration of the probiotic prepared in example 3;
experiment group 4: intestinal tract preparation and postoperative administration of physiological saline;
control group: SD rats were not treated with any treatment and were normally fed.
The observations and index measurements are as follows:
(1) Intestinal flora analysis: medium selection: bifidobacteria were identified using BS blood agar plates and counted as viable plate count, and the log of Colony Forming Units (CFU) per gram of wet fecal weight was calculated.
(2) Measurement of intestinal mucosa permeability index serum diamine oxidase (DAO) level
Orbital bleeding was performed on each group of rats 1 day before magnesium sulfate intestinal tract preparation, and serum was obtained by centrifugation, and serum diamine oxidase (DAO) levels of each group of rats before the experiment were measured;
on the 6 th day after operation, after tail breaking and blood taking of each group of rats, centrifuging to obtain serum, and measuring the serum diamine oxidase (DAO) level;
serum diamine oxidase (DAO) levels were measured using an enzyme-linked immunosorbent assay.
Statistical method
Statistical treatment all data were statistically analyzed using SPSS18.0, t-test, and χ -count data 2 And the difference is statistically significant when the P is less than or equal to 0.05.
2. Test results
The intestinal flora changes in the removed blind feces on postoperative day 6 for different groups of SD rats are shown in table 2.
Table 2 intestinal flora (mean.+ -. SD, lgCFU/g) on postoperative day 6 in different groups of SD rats
Group of Bifidobacterium strain
Control group 8.45±0.79
Experiment group 1 7.86±0.63**
Experiment group 2 6.22±0.54*
Experiment group 3 6.61±0.58**
Experiment group 4 5.77±0.47**
Note that: p <0.05, < p <0.01, compared to the control group.
As can be seen from table 2, the probiotics prepared in examples 1 to 3 are effective in improving the rapid recovery of the intestinal bifidobacteria flora, compared with the control group. And it can be seen from the data of experimental groups 1-3 that sodium alginate, konjak mannan, xylan and L-arabinose and chitosan can synergistically improve intestinal flora recovery.
The changes in diamine oxidase (DAO) levels in serum 1 day (pre-experiment) and 6 days (post-experiment) after surgery in the magnesium sulfate intestinal tract are shown in Table 3 for different groups of SD rats
TABLE 3 diamine oxidase (DAO) levels (mean.+ -. SD, pg/ml) in serum from SD rats of different groups 1 day before magnesium sulfate intestinal tract preparation (before experiment) and 6 days after surgery (after experiment)
Group of The first 1 day of preparation of magnesium sulfate intestinal tract Day 6 post-operation
Control group 0.74±0.04 0.76±0.06
Experiment group 1 0.76±0.03 0.85±0.05**
Experiment group 2 0.73±0.05 1.06±0.07**
Experiment group 3 0.76±0.06 0.99±0.07*
Experiment group 4 0.76±0.06 1.16±0.07**
Note that: p <0.05, p <0.01 compared to day 6 post-surgery in the control group.
Intestinal resection after intestinal preparation is easy to lead to the increase of intestinal mucosa permeability, thereby destroying the barrier function of the intestinal mucosa, and diamine oxidase (DAO) in serum is an index of the intestinal mucosa permeability. From experimental groups 1-4 in Table 3, it can be seen that the level of diamine oxidase (DAO) in the post-intestinal resection serum increases, indicating that post-intestinal resection increases intestinal mucosa permeability and disrupts intestinal mucosa barrier function. The significantly smaller magnitude of diamine oxidase (DAO) rise in the serum of experimental group 1-3 compared to experimental group 4 (intestinal preparation and post-operative administration of normal saline) compared to experimental group 4, and in particular, the significantly reduced magnitude of rise in experimental group 1, indicates that the microecologics administered in experimental group 1-3 can significantly inhibit the increase in mucosal permeability caused by intestinal resection after intestinal preparation, thereby effectively protecting the intestinal mucosal barrier.
The foregoing description is only of the preferred embodiments of the present application and is not intended to limit the same, but rather, various modifications and variations may be made by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims (3)

1. The microecological preparation is characterized by comprising a strain, sodium alginate, konjak mannan, xylan, L-arabinose and chitosan;
the strain is bifidobacterium; the xylan is arabinoxylan;
the weight ratio of the sodium alginate to the konjak mannan to the xylan to the L-arabinose is (1-3): (0.2-0.4): (5-7): (0.8-1.2);
the microecological preparation is prepared by the following method, and the method comprises the following steps:
(1) Mixing sodium alginate, konjak mannan, arabinoxylan and L-arabinose with water to obtain a polysaccharide solution, wherein the content of the sodium alginate, konjak mannan, arabinoxylan and L-arabinose is respectively 1-3wt%, 0.2-0.4wt%, 5-7wt% and 0.8-1.2wt%, based on the total weight of the polysaccharide solution;
(2) Sterilizing the polysaccharide solution at 121deg.C for 20min, and cooling to room temperature; uniformly mixing the bifidobacterium suspension with a polysaccharide solution according to the volume ratio of 1:10, extruding the mixture into 0.3mol/L calcium chloride solution by using a syringe, standing the mixture at the room temperature of 25 ℃ for 30min, filtering the mixture, and cleaning the mixture with sterile water for 2 times to obtain a precipitate primary microecological preparation;
(3) Dissolving 4.0. 4.0g chitosan with 950mL of 0.1mol/L acetic acid solution, adjusting the pH value of the solution to 6.0 with 1.0mol/L NaOH solution, filtering, and fixing the volume to 1000mL to obtain chitosan solution; 15.0g of the prepared primary microecological preparation is added into a chitosan solution prepared by 100mL, stirred for 30min at a constant temperature of 180r/min at 37 ℃, gauze is filtered to collect the secondarily embedded microecological preparation, and the secondarily embedded microecological preparation is obtained by low-temperature freeze-drying after being washed twice with a sterile 8.5g/L NaCl solution.
2. The probiotic apparatus of claim 1, wherein said bifidobacterium is present in a concentration of 10 in said bacterial suspension 9 ~10 10 CFU/ml。
3. The probiotic formulation of claim 1, wherein in step (2), the volume ratio of polysaccharide solution to bacterial suspension is 8-12:1.
CN202011294300.7A 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology Active CN112370470B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011294300.7A CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011294300.7A CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Publications (2)

Publication Number Publication Date
CN112370470A CN112370470A (en) 2021-02-19
CN112370470B true CN112370470B (en) 2023-05-26

Family

ID=74584209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011294300.7A Active CN112370470B (en) 2020-11-18 2020-11-18 Microecological preparation for reconstructing intestinal microecology

Country Status (1)

Country Link
CN (1) CN112370470B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112401242B (en) * 2020-11-18 2023-07-25 复旦大学附属中山医院 Microecological preparation for reconstructing intestinal microecology and application thereof
CN113854569A (en) * 2021-08-25 2021-12-31 河北天烨食品科技有限公司 Probiotic nutrient, preparation method thereof and method for improving survival rate of edible probiotics
CN114698729B (en) * 2022-03-30 2023-01-10 播恩集团股份有限公司 Microecological preparation containing 5-methyltetrahydrofolic acid and preparation method and application thereof
CN114917292A (en) * 2022-05-31 2022-08-19 湖南航天医院 Intestinal microecological preparation for preventing and treating intestinal inflammatory diseases
CN115227728A (en) * 2022-05-31 2022-10-25 湖南航天医院 Intestinal microecological preparation and preparation method thereof
CN115024374B (en) * 2022-06-15 2023-11-24 黄淮学院 Preparation method and application of candy containing immobilized probiotics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111671791A (en) * 2020-05-25 2020-09-18 中山大学 Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3002444B1 (en) * 2013-02-25 2015-03-13 Oreal COSMETIC COMPOSITION OF GEL TYPE
CN104887647B (en) * 2014-03-08 2017-12-01 复旦大学 Probiotic double layer microcapsules and preparation method thereof
RU2652277C1 (en) * 2017-04-13 2018-04-25 Артем Михайлович Гурьев Microcapsules, containing living microorganisms, and their application
CN109528683A (en) * 2018-12-13 2019-03-29 浙江华康药业股份有限公司 A kind of arabinose fixed point release produces the regulation method of butyric to enteral

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111671791A (en) * 2020-05-25 2020-09-18 中山大学 Micro-ecological composition for improving constipation by targeting intestinal flora and preparation thereof

Also Published As

Publication number Publication date
CN112370470A (en) 2021-02-19

Similar Documents

Publication Publication Date Title
CN112370470B (en) Microecological preparation for reconstructing intestinal microecology
US7101565B2 (en) Probiotic/prebiotic composition and delivery method
KR101493302B1 (en) Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
AU2004228936B2 (en) Synbiotic combination
Bosscher et al. Inulin and oligofructose as prebiotics in the prevention of intestinal infections and diseases
CN108004189A (en) A kind of compound probiotic lactic acid bacteria powder and preparation method and application
CN110959866A (en) High-fiber chewable tablet containing probiotics and preparation method thereof
JPH03151854A (en) Composition for improving intestinal environment
CN112970990A (en) Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof
CN116549494B (en) Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof
CN116855413B (en) Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof
CN112401242B (en) Microecological preparation for reconstructing intestinal microecology and application thereof
KR102000170B1 (en) Food compositions for reducing body fat and improving intestinal function
KR20040037011A (en) Food Composition Containing a Lactic Acid Bacteria
JP2004269407A (en) Constipation ameliorant and food and beverage containing the same
CN109700833B (en) Pharmaceutical composition for treating constipation and preparation method and application thereof
CN116869169B (en) Composition with function of relaxing bowels and preparation method and application thereof
CN111265627B (en) Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof
CN114711435B (en) Dietary fiber probiotic composition and preparation method thereof
CN115737599A (en) Colorectal-release intestinal bacterium microcapsule
EP4088726A1 (en) Composition for use in preventing or treating diarrhea, constipation or irritable bowel syndrome with fibers formed of beta-1-4-glucan
CN116869106A (en) Probiotic solid beverage and preparation method thereof
JP6116174B2 (en) Oral composition for improving bowel movements

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant